Antibody Drug Conjugates

Stalin Bala; Siva K Prasad

doi:10.4103/ijmpo.ijmpo_313_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(06): 889-892
DOI: 10.4103/ijmpo.ijmpo_313_20

Trainee’s Corner

Antibody Drug Conjugates

Stalin Bala

Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India

,

Siva K Prasad

Department of Medical Oncology, Santhiram Medical College and General Hospital, Nandyal, Andhra Pradesh, India

› Author Affiliations

Abstract

Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released, which finally leads to cell killing. Payloads are broadly divided into tubulin-disrupting agents and DNA-damaging agents. Most of the current ADCs utilize humanized mAbs, and fully human mAbs are under investigation. ADC development process is accelerated by better designing and bio-engineering methods.

Keywords

Antibody drug conjugate - linker - monoclonal antibody

Full Text

References

References
1 356-india-fact-sheets.pdf. Available from: https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf. [Last accessed on 2020 Jun 03].
2 Census of India Website: Causes of Death Statistics. Available from: https://censusindia.gov.in/vital_statistics/causesofdeath.html. [Last accessed on 2020 May 23].
3 Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008; 8: 473-80
4 Kanellos J, Pietersz GA, McKenzie IF. Studies of methotrexate-monoclonal antibody conjugates for immunotherapy. JNCI J Natl Cancer Inst 1985; 75: 319-32
5 Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM. et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261: 212-5
6 Strohl WR. Current progress in innovative engineered antibodies. Protein Cell 2018; 9: 86-120
7 Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody–drug conjugates: A comprehensive review. Mol Cancer Res 2020; 18: 3-19
8 Hughes B. Antibody-drug conjugates for cancer: Poised to deliver?. Nat Rev Drug Discov 2010; 9: 665-7
9 Casi G, Neri D. Noninternalizing targeted cytotoxics for cancer therapy. Mol Pharm 2015; 12: 1880-4
10 Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ. et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 2008; 19: 759-65
11 Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 2018; 9: 33-46
12 Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy. J Cell Physiol 2018; 233: 6441-57
13 Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required? Br J Cancer 2017; 117: 1736-42
14 García-Alonso S, Ocaña A, Pandiella A. Resistance to antibody-drug conjugates. Cancer Res 2018; 78: 2159-65